In this segment of the Motley Fool Money podcast, host Chris Hill, Million Dollar Portfolio's Jason Moser and Matt Argersinger, and Total Income's Ron Gross talk about why Teladoc (NYSE:TDOC) is doing as well as it is. It's a well-run company, of course, but it helps that regulatory barriers are falling and that telehealth is doing one of the things that people want most in the healthcare segment today: provide quality care at a lower price.

A full transcript follows the video.

This video was recorded on March 2, 2017.

Chris Hill: Speaking of IPOs, Teladoc, which has been public for less than three years, shares hit a new high this week. Strong fourth quarter results. The first year or so, Jason, of Teladoc's public life, a little rocky. But it really seems like they have their sea legs now.

Jason Moser: Yeah. And I'll tell you, I had some really great discussions with some of the physicians at our event in San Francisco a couple weeks back. It was a lot of fun kicking this name around. I think, when it comes to virtual healthcare, we're going to be biggest risks early on has been in the form of regulatory barriers. I think a lot of people couldn't quite make that leap. And that makes a lot of sense. I think what we're seeing now, though, is that risk is fading away very quickly. The nature of telehealth and virtual healthcare is terrific. It's scalable, it's affordable, it really helps to reshape a healthcare system that's in dire need.

So, this company, Teladoc, continues to chalk up really great results. All the metrics are pointing in the right direction. Revenue is up, users are up, utilization is up. They continue to forge new agreements with big providers. They just landed the Blue Cross Blue Shield Federal Employee Program. And I'll just say that I'm a member of that thanks to my lovely wife, so now I'm a Teladoc shareholder and a Teladoc customer. But, yeah, I think they've set the target for free cash flow positive in 2020, which means the market has set that expectation. I'm expecting big things from this stock.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.